What changed recently
Newly published and updated guidelines across every system, newest first. Each entry links to the official source.
8 older updates are outside this window. Show all time
- Infectious DiseaseGLOBAL2026-04-012021 → 2026Sepsis & septic shock
The 2026 edition expands to 129 statements, 46 of them on questions the 2021 guidelines never addressed, including a conditional recommendation for point-of-care ultrasound to guide resuscitation and new guidance on active fluid removal once initial resuscitation is complete. Of the 38 questions carried over from 2021, only three recommendations actually reversed direction.
- Infectious DiseaseUS2025-10-142023 guideline → Living guideline, updated October 2025COVID-19
The October 2025 antiviral update reframed treatment decisions around preventing hospitalisation rather than death, given higher population immunity. It keeps a strong recommendation for nirmatrelvir/ritonavir in adults at high risk of progression but now suggests against routine antiviral treatment in mild to moderate COVID-19 without risk factors.
source ↗curation confidence 80% - Infectious DiseaseEU2025-10-0112.1 → 13.0HIV
Version 13.0 restructured the guidelines into two parts, added a new consolidated Substance Use section covering alcohol, opioid use and chemsex, and extensively rewrote the obesity guidance to cover pharmacotherapy and bariatric surgery. Recommended first-line ART regimens for treatment-naive adults were left unchanged from v12.1, and the lipodystrophy section was retired.
- Infectious DiseaseUS2025-09-25September 12, 2024 update → Living guideline, updated September 2025HIV
The September 2025 revision added a dedicated chapter on cardiovascular and metabolic complications as people with HIV approach normal life expectancy, and retired the standalone statin primary-prevention section in favour of the ACC/AHA multisociety dyslipidaemia guidance. It also revised laboratory monitoring intervals, added subsections on starting ART in early infection and in hospitalised patients, and expanded cost guidance around long-acting injectables.
source ↗curation confidence 90%